Kernal gets $48M to develop easier, cheaper CAR T-cell therapies
Kernal has been awarded up to $48M funding to accelerate the development of KR-402, a next-generation in vivo CAR T-cell therapy.| Multiple Sclerosis News Today
Kernal has been awarded up to $48M funding to accelerate the development of KR-402, a next-generation in vivo CAR T-cell therapy.| Multiple Sclerosis News Today
